Entresto Facing Pressure From Diabetes Drugs

With diabetes therapeutics adding cardiovascular risk reduction claims, Novartis's heart failure drug Entresto could face pressure from new fronts – just as sales start to take off.

Pressure
SGLT2 inhibitors, already approved for diabetes, could soon disrupt Novartis's Entresto plans in CHF • Source: Shutterstock

The demonstration of reduced heart failure, death and other cardiovascular benefits with major classes of diabetes drugs means cardiovascular products like Novartis AG's congestive heart failure therapy Entresto must deal with imminent – and unexpected – competition from marketed metabolic drugs broadening their reach.

See Related Story

For more on Entresto's performance over time: (Also see "Novartis's Entresto Voyage: Hindsight Is 20/20" - Scrip, 15 May, 2017.)

Entresto (valsartan/sacubitril) has finally started to make its mark on the CHF market, but there are other products moving up...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

Aerovate Tanks On Trial Catastrophe

 

A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?    

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

Kerendia Could Be Next Jewel In Bayer's Pharma Crown

 
• By 

CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.